Tivozanib Could Be Evaluated in Combination Regimens for Renal Cell Carcinoma
Vivek Subbiah, MD, discusses the potential to combine tivozanib with other agents, particularly ipilimumab, as treatment of patients with renal cell carcinoma.
Vivek Subbiah, MD, of the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the potential to combine tivozanib (Fotivda) with other agents, particularly ipilimumab (Yervoy),as treatment of patients with renal cell carcinoma (RCC).
It is challenging to compare a VEGFR tyrosine kinase inhibitor (TKI) with another VEGFR TKI. This can only be performed in a randomized study, says Subbiah. A single-arm study would show responses, but it would be best to perform this type of analysis in a multi-arm randomized clinical trial.
Subbiah says this is also why it is important that all patients with RCC go on clinical trials. By doing so, investigators could get any idea on real-world outcomes with tivozanib or other treatment options in the landscape.
The combination of tivozanib plus ipilimumab is a great idea, says Subbiah, because the VEGFR TKI has a longer half-life. Preclinical data have also shown that the agent is synergistic with checkpoint blockade.
<< View more resources and information regarding renal cell carcinoma
Advances in Subsequent Therapies Shake Up Sequencing of ccRCC Treatment
April 25th 2024With the approval of belzutifan and other newer data for treating patients with recurrent renal cell carcinoma, the state of subsequent therapies is advancing beyond the reuse of frontline options with impacts on duration of response and quality of life.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Long-Term Ipi/Nivo RCC Data Show Durability Across Risk Groups
April 12th 2024During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the 8-year follow-up data of ipilimumab plus nivolumab in patients with advanced renal cell carcinoma In the first article of a 2-part series.
Read More
